Day One Biopharmaceuticals amends bylaws for universal proxy rules and DGCL updates

Day One Biopharmaceuticals, Inc.

Bylaws revised to comply with SEC universal proxy rules (Rule 14a-19) and recent Delaware law changes.
Advance notice provisions updated: additional disclosures, nominee interview requirement, proxy card color rule.
Stockholders using universal proxy must certify compliance and provide evidence 5 business days before meeting.
Emergency bylaw provision added to allow Board quorum during crises.
Changes effective Feb 17, 2023; no impact on financials or operations.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Day One Biopharmaceuticals, Inc.: Amended and restated bylaws to align with universal proxy rules, DGCL amendments, and other changes (effective 2023-02-17).

Change: bylaw amendment
Effective: 2023-02-17

Exact text from the filing

On February 17, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Day One Biopharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-046522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.